HUMA Humacyte, Inc.
Humacyte, Inc. (HUMA) is expected to report earnings on November 11, 2026, before the market open. The consensus earnings estimate is a loss of $0.09 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.1% since its last earnings release on August 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Humacyte, Inc.
Humacyte, Inc. is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine.
Sector
Healthcare
Industry
Biotechnology